Listed

Enveric Biosciences, Inc.: Form 10-Q for the period ended Mar 31, 2023

Filed with the SEC on May 15, 2023 and accepted by EDGAR at May 15, 2023, 09:25 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2023-01-01 to 2023-03-31$2.0mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2023-01-01 to 2023-03-31−$4.9mus-gaap:OperatingIncomeLoss
Interest expense3 months2023-01-01 to 2023-03-31$11us-gaap:InterestExpense
Net income3 months2023-01-01 to 2023-03-31−$4.7mus-gaap:NetIncomeLoss
Basic EPS3 months2023-01-01 to 2023-03-31−$2.31us-gaap:EarningsPerShareBasic
Operating cash flow3 months2023-01-01 to 2023-03-31−$5.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2023-01-01 to 2023-03-31$5.2kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2023-03-31$12.6mus-gaap:Cash
Current assetsAt period end2023-03-31$14.8mus-gaap:AssetsCurrent
Total assetsAt period end2023-03-31$15.9mus-gaap:Assets
Current liabilitiesAt period end2023-03-31$4.4mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2023-03-31$10.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-23-016990. Last ingested by Listed: Nov 14, 2026, 20:02 ET. Listed shows no prices and gives no investment advice.